HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 07-07-2006, 11:44 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,780
FDG PET predicts survival in metastatic breast cancer

FDG PET is the standard PET scan performed.

This study was not done in her2+ breast cancer only--I will try to review the original and get back to you if its share of her2 (if identified) were either very high or very low.

FDG-PET predicts metastatic breast cancer survival
[18F]Fluorodeoxyglucose positron emission tomography (FDG-PET) can predict the prognosis of patients receiving treatment for advanced breast cancer, study findings from Australia suggest.

Rodney Hicks (The Peter MacCallum Cancer Centre, East Melbourne, Victoria) and colleagues used the technique to follow-up 47 women with metastatic breast cancer undergoing up to three cycles of high-dose chemotherapy with autologous stem cell transplantation.

The patients were examined for therapeutic response 1 month after their last treatment cycle using conventional imaging – including computed tomography (CT), ultrasound, mammography, and bone scanning, as indicated – and FDG-PET.

While CT or ultrasound indicated a complete response to treatment in 37% of patients and a partial response in 35%, FDG-PET suggested a complete metabolic response to chemotherapy in 72% of the group.

Importantly, FDG-PET was the strongest independent predictor of survival in the patients, with patients with a negative FDG-PET result achieving significantly longer median survival than those with positive findings (24 vs 10 months).

Furthermore, in multivariate analysis, the relative risk of death was greatest in patients with a positive post-treatment FDG-PET result, prior anthracycline therapy, and evidence of visceral metastasis, with values of 5.3, 3.3, and 2.4, respectively.

"A single FDG-PET study performed after completion of high-dose chemotherapy for metastatic breast cancer can powerfully stratify for survival," Hicks et al summarize in the Journal of Clinical Oncology.

"This may have implications for how we should assess outcome after conventional-dose therapy for metastatic breast cancer and warrants additional study," they believe.



J Clin Oncol 2006; 24: 3026–3031

http://www.jco.org/cgi/content/abstract/24/19/3026
© 2006 CMG
Lani is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 03:25 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter